Definium Therapeutics (DFTX) Reiterated at Buy by Stifel After Analyst Day

April 24, 2026 8:03 AM

Stifel analyst Paul Matteis reiterated a Buy rating and $30.00 price target on Definium Therapeutics Inc (NASDAQ: DFTX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found